AstraZeneca and Pharmacyclics enter clinical trial collaborations in oncology
Studies planned to evaluate IMBRUVICA® in combination with AstraZeneca investigational therapies for the treatment of solid tumours and haematological cancersAstraZeneca and Pharmacyclics, Inc. today announced that they have entered into clinical trial collaborations to evaluate novel combination therapies targeting solid tumours and a number of haematological cancers. The first collaboration, focusing on solid tumours, will evaluate the efficacy and safety of IMBRUVICA® (ibrutinib), Pharmacyclics’ oral Bruton's tyrosine kinase inhibitor in combination with AstraZeneca’s anti-PD-L1